Search

Displaying results 3241 - 3250 of 7479 in total
  1. Drug

    Methyl-D9-choline

    go.drugbank.com/drugs/DB12628
    Investigational

    Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

  2. Drug

    DA-6886

    go.drugbank.com/drugs/DB12853
    Investigational

    DA-6886 has been used in trials studying the treatment of Irritable Bowel Syndrome.

  3. Drug

    Oxibendazole

    go.drugbank.com/drugs/DB04910
    ExperimentalVet approved

    Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.

  4. Drug

    Vasopressin

    go.drugbank.com/drugs/DB00067
    ApprovedInvestigational

    Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour. Vasopressin is v...

    Products: VASOPRESSIN INJECTION USP 20 u/ml, VASOPRESINA INYECTABLE 20 U/ML USP
  5. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.

  6. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.

  7. Drug

    Primaquine

    go.drugbank.com/drugs/DB01087
    ApprovedInvestigational

    An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide.

  8. Drug

    Nitrous acid

    go.drugbank.com/drugs/DB09112
    ApprovedInvestigational

    Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning.

  9. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].

  10. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.